Suhy's Talk at Bio-Investor Forum, page-8

Very interesting. As the shrna levels where taken at 21 days, these numbers represent a higher than expected result (based on pre-clinical findings). The numbers are also in the ranges that one would expect to see ~99% reduction in viral replication. I guess the company is waiting for more data before making any claim on a successful treatment but, if the replicon model data is accurate, then I would say that TT-034 is going to be announced as a success.

The next press release is going to be even more interesting.